Enanta Pharmaceuticals, Inc (ENTA)

Price$11.28

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-28.04%

Price vs S&P 500 (4W)-26.46%

VGM Score44.42

Market Capitalization$328.00M

All Metrics

Book Value / Share (Quarterly)$4.01

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.83%

Cash Flow / Share (Quarterly)$-0.33

Price vs S&P 500 (YTD)-36.63%

Net Profit Margin (TTM)-89.56%

EPS (TTM)$-2.59

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-2.59

Revenue Growth (5Y)-11.82%

EPS (Annual)$-3.84

ROI (Annual)-39.39%

Net Profit Margin (5Y Avg)-137.71%

Cash / Share (Quarterly)$5.64

Revenue Growth QoQ (YoY)14.96%

ROA (Last FY)-29.17%

Revenue Growth TTM (YoY)7.37%

EBITD / Share (TTM)$-2.21

ROE (5Y Avg)-67.21%

Operating Margin (TTM)-87.24%

Cash Flow / Share (Annual)$-1.50

P/B Ratio2.81x

P/B Ratio (Quarterly)3.14x

Net Income / Employee (Annual)$-682,400

EV / Revenue (TTM)6.11x

Net Interest Coverage (TTM)12.65x

ROA (TTM)-20.22%

EV / EBITDA (TTM)28.63x

EPS Incl Extra (Annual)$-3.84

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)3.69x

3-Month Avg Trading Volume0.18M

52-Week Price Return56.45%

Revenue / Employee (TTM)$576,800

Tangible BV / Share (Quarterly)$10.29

P/S Ratio (Annual)5.02x

Asset Turnover (Annual)0.23x

52-Week High$17.15

Operating Margin (5Y Avg)-148.06%

EPS Excl Extra (Annual)$-3.84

CapEx CAGR (5Y)54.82%

Tangible BV CAGR (5Y)-11.25%

26-Week Price Return-20.11%

Quick Ratio (Annual)4.03x

13-Week Price Return-17.90%

Total Debt / Equity (Annual)2.21x

Current Ratio (Quarterly)3.84x

Enterprise Value$423.16M

Revenue / Share Growth (5Y)-13.04%

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-33.15%

Revenue / Employee (Annual)$544,400

Pretax Margin (Annual)-127.90%

Cash / Share (Annual)$8.83

3-Month Return Std Dev49.26%

Net Income / Employee (TTM)$-516,500

ROE (Last FY)-126.53%

Net Interest Coverage (Annual)-19.08x

EPS Basic Excl Extra (Annual)$-3.84

P/FCF (TTM)18.90x

Receivables Turnover (TTM)9.48x

Total Debt / Equity (Quarterly)1.12x

EPS Incl Extra (TTM)$-2.59

Receivables Turnover (Annual)9.66x

ROI (TTM)-26.22%

P/S Ratio (TTM)4.74x

Pretax Margin (5Y Avg)-144.00%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$10.29

Price vs S&P 500 (52W)32.08%

Year-to-Date Return-28.47%

5-Day Price Return-10.97%

EPS Normalized (Annual)$-3.84

ROA (5Y Avg)-27.87%

Net Profit Margin (Annual)-125.36%

Month-to-Date Return-14.29%

Cash Flow / Share (TTM)$-6.26

EBITD / Share (Annual)$-3.79

Operating Margin (Annual)-130.65%

LT Debt / Equity (Annual)1.74x

ROI (5Y Avg)-39.39%

LT Debt / Equity (Quarterly)0.85x

EPS Basic Excl Extra (TTM)$-2.59

P/TBV (Quarterly)0.97x

P/B Ratio (Annual)3.95x

Pretax Margin (TTM)-89.42%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-26.16%

Beta1.02x

P/FCF (Annual)58.16x

Revenue / Share (TTM)$2.38

ROE (TTM)-64.04%

52-Week Low$6.43

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q2 26-0.45est. -0.50

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

4.15

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ENTAEnanta Pharmaceuticals, Inc	C	C	C	$11.28
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Enanta Pharmaceuticals is a biotechnology company specializing in small-molecule drug discovery for virology and immunology. Its pipeline includes candidates for RSV, SARS-CoV-2, hepatitis B, and type 2 inflammatory disease. The company generates revenue primarily through royalties, including from its collaboration with AbbVie.